What Is China Pharma Holdings, Inc. (CPHI) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, China Pharma Holdings, Inc.'s intrinsic value is estimated at $0.25. Trading at its current price of $1.10, the valuation engine raises significant caution: 10 of 10 models flag downside risk, projecting an average implied return of -76.9%. Notably, FTNN sees the most upside at -26.4% (fair value: $0.81), while First Chicago is the most conservative at -98.4% ($0.02). The spread between these extremes — +72.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CPHI?
10 of 13 models are currently active for CPHI. All 10 active models suggest the stock trades above fair value. The Bayesian DCF estimates CPHI's intrinsic value at $0.14, implying -86.9% downside from the current price. See which stocks rank higher →
How Does CPHI Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, CPHI ranks #356 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For China Pharma Holdings, Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is CPHI a Value Trap?
CirclFi's Value Trap algorithm assigns CPHI a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for China Pharma Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, China Pharma Holdings, Inc. scores 3.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +72.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CPHI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CPHI's 10 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad